Sanofi Raises 2026 Profit Outlook Following Strong Dupixent Sales
Sanofi (SNY) has upgraded its full-year 2026 profit guidance following a robust third-quarter performance. The upward revision is primarily driven by the sustained commercial success of its blockbuster drug, Dupixent, and strong momentum across its broader pharmaceutical launch portfolio. The company reported third-quarter business earnings of €3.55 per share, exceeding market expectations. This growth highlights Sanofi's ability to leverage high-demand specialty medicines to drive long-term profitability and strengthen its financial outlook.
Tickers: $SNY
Topics: earnings beat guidance raise pharmaceuticals
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)